The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Cost Savings

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cost Savings


Psychiatry related information on Cost Savings

  • OBJECTIVE: To estimate per-patient potential cost savings using rivastigmine in the treatment of Alzheimer's disease (AD) in Canada. BACKGROUND: In recent years, new members of a class of pharmaceuticals known as cholinesterase inhibitors have been introduced for the treatment of patients with AD [6].
  • Based on analysis of sildenafil data, oral therapy of erectile dysfunction provides substantial cost savings when compared with other treatment options and contributes insignificant overall costs to health plans [7].

High impact information on Cost Savings

  • The cost savings per patient (in U.S. dollars, inclusive of the cost of ketoconazole) was about $5,200 in the first year and about $3,920 in each subsequent year [8].
  • RESULTS: Propranolol results in cost savings ranging between $450 and $14,600 over a 5-year period [9].
  • Secondary prevention with a statin seems to be cost-effective for all risk subgroups and is cost-saving in some high-risk subgroups [10].
  • Treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home [11].
  • It can also lead to a return in clindamycin susceptibility among isolates and can effect cost savings to the hospital [12].

Chemical compound and disease context of Cost Savings

  • Although clarification of some methodological issues would be beneficial, the available efficacy data, together with the practical advantages of LMWHs in general, suggest that enoxaparin is an effective and convenient means of treating unstable angina and should provide cost savings compared with UFH [13].
  • CONCLUSIONS: Transitioning from intravenous midazolam to enterally administered lorazepam in critically ill children who require long-term sedation results in significant cost savings [14].
  • The cost per bleeding episode averted was highly dependent on the risk of hemorrhage and, to a lesser degree, on the efficacy of sucralfate prophylaxis, ranging from a cost per bleeding episode averted of $103,725 for low-risk patients to cost savings for very high-risk patients [15].
  • A second cost-benefit analysis, conducted in Canada, suggested that use of amifostine in patients with advanced ovarian cancer would be cost saving [16].
  • Before a 1996 US regulation requiring fortification of enriched cereal-grain products with folic acid, 3 economic evaluations projected net economic benefits or cost savings of folic acid fortification resulting from the prevention of pregnancies affected by a neural tube defect [17].

Biological context of Cost Savings


Anatomical context of Cost Savings


Associations of Cost Savings with chemical compounds

  • CONCLUSIONS: The chlorhexidine-silver sulfadiazine catheter is well tolerated, reduces the incidence of catheter-related infection, extends the time that noncuffed central venous catheters can be safely left in place for the short term, and should allow cost savings [28].
  • RESULTS: The cost of pamidronate therapy exceeded the cost savings from prevented adverse events [29].
  • For younger women in the highest risk groups, chemoprevention with tamoxifen was estimated to have cost savings or be cost-effective, both with and without quality adjustments [30].
  • In view of the simplicity and probable cost savings attached to single-agent treatment, a melphalan/prednisone regimen should be considered as initial therapy for all patients with myeloma [31].
  • Prophylaxis was cost-saving if the ulcer complication rate was > 1.5%, or if the 3-month price of misoprostol was < or = $95 [32].

Gene context of Cost Savings

  • Treating acute ischemic stroke patients with tPA within 3 hours of symptom onset improves functional outcome at 3 months and is likely to result in a net cost savings to the health care system [33].
  • CONCLUSIONS: Over a 6 month period, withdrawing FP in a pre-selected trial population of COPD patients led to absolute cost savings but with a higher rate of exacerbations and hospital admissions [34].
  • METHODS: Decision analysis techniques are used to compare the outcome, utility, and incremental cost savings of a plan to screen voluntary blood donors and their siblings for hemochromatosis using a genotypic test (C282Y mutation) with phenotypic tests (transferrin saturation, serum ferritin) [35].
  • CONCLUSION: MTX is cost effective (cost saving vs the no second line agent option) for MTX-naive RA in achieving ACR 20 or ACR 70WR over a 6 month period [36].
  • CONCLUSION: In this study population of concomitant coumarin and NSAID users, the reduction in bleeding complications with the use of more expensive COX-2-selective inhibitors was associated with net medical cost savings compared with nonselective NSAIDs [37].

Analytical, diagnostic and therapeutic context of Cost Savings

  • Routine use of G-CSF in SCLC patients treated with standard-dose chemotherapy appears to be expensive and is not associated with an obvious therapeutic benefit or cost savings [38].
  • Content: On the basis of the positive impact that the rapid intraoperative PTH test has had on both patient outcomes and cost savings, other rapid intraoperative hormone immunoassays for the diagnosis and/or treatment of other endocrine-hormone-secreting tumors have been developed [39].
  • These observations suggest that perioperative stroke after CEA/CAB is related to patient selection and that low-risk patients can undergo CEA/CAB with the benefits of low morbidity, patient convenience, and cost savings from avoiding a second hospitalization and operation [40].
  • Sensitivity analyses demonstrated that the cost savings observed were maintained over a wide range of alternative values for both unit costs and resource utilization, including length of hospital stay, time spent in intensive care units, bed day costs and the cost of lipid formulations of amphotericin B [41].
  • The incidence of postoperative infections was not different between regimens, irrespective of the type of hysterectomy, but considerable cost-savings by reduced drug and administration expenses were realized with the single-dose cefotaxime regimen [42].


  1. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Hollak, C.E., Aerts, J.M., Goudsmit, R., Phoa, S.S., Ek, M., van Weely, S., von dem Borne, A.E., van Oers, M.H. Lancet (1995) [Pubmed]
  2. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Fass, R., Fennerty, M.B., Ofman, J.J., Gralnek, I.M., Johnson, C., Camargo, E., Sampliner, R.E. Gastroenterology (1998) [Pubmed]
  3. Potential cost savings of erythropoietin administration in end-stage renal disease. Hynes, D.M., Stroupe, K.T., Greer, J.W., Reda, D.J., Frankenfield, D.L., Kaufman, J.S., Henderson, W.G., Owen, W.F., Rocco, M.V., Wish, J.B., Kang, J., Feussner, J.R. Am. J. Med. (2002) [Pubmed]
  4. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. Ward, R.E., Gheorghiade, M., Young, J.B., Uretsky, B. J. Am. Coll. Cardiol. (1995) [Pubmed]
  5. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Chen, J.J., Frame, D.G., White, T.J. Arch. Intern. Med. (1998) [Pubmed]
  6. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Hauber, A.B., Gnanasakthy, A., Mauskopf, J.A. Clinical therapeutics. (2000) [Pubmed]
  7. Health care cost implications of sildenafil citrate. Miner, M. The journal of sexual medicine. (2004) [Pubmed]
  8. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. Keogh, A., Spratt, P., McCosker, C., Macdonald, P., Mundy, J., Kaan, A. N. Engl. J. Med. (1995) [Pubmed]
  9. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Teran, J.C., Imperiale, T.F., Mullen, K.D., Tavill, A.S., McCullough, A.J. Gastroenterology (1997) [Pubmed]
  10. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Prosser, L.A., Stinnett, A.A., Goldman, P.A., Williams, L.W., Hunink, M.G., Goldman, L., Weinstein, M.C. Ann. Intern. Med. (2000) [Pubmed]
  11. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Gould, M.K., Dembitzer, A.D., Sanders, G.D., Garber, A.M. Ann. Intern. Med. (1999) [Pubmed]
  12. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Climo, M.W., Israel, D.S., Wong, E.S., Williams, D., Coudron, P., Markowitz, S.M. Ann. Intern. Med. (1998) [Pubmed]
  13. Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Noble, S., Spencer, C.M. Drugs (1998) [Pubmed]
  14. A cost analysis of enterally administered lorazepam in the pediatric intensive care unit. Lugo, R.A., Chester, E.A., Cash, J., Grant, M.J., Vernon, D.D. Crit. Care Med. (1999) [Pubmed]
  15. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem, T., McCarthy, B.D., Fogel, R., Schiffman, R.M., Patel, R.V., Zarowitz, B.J., Nerenz, D.R., Bresalier, R.S. Crit. Care Med. (1996) [Pubmed]
  16. Pharmacoeconomics of amifostine in ovarian cancer. Calhoun, E.A., Bennett, C.L. Semin. Oncol. (1999) [Pubmed]
  17. Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. Grosse, S.D., Waitzman, N.J., Romano, P.S., Mulinare, J. American journal of public health. (2005) [Pubmed]
  18. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. Younossi, Z.M., McHutchison, J.G., Ganiats, T.G. J. Hepatol. (1997) [Pubmed]
  19. Targeted estrogen/progesterone replacement therapy for osteoporosis: calculation of health care cost savings. Clark, A.P., Schuttinga, J.A. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1992) [Pubmed]
  20. Usefulness of a rapid human immunodeficiency virus-1 antibody test for the management of occupational exposure to blood and body fluid. Landrum, M.L., Wilson, C.H., Perri, L.P., Hannibal, S.L., O'Connell, R.J. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America. (2005) [Pubmed]
  21. A pharmacoeconomic analysis of Neoral without intravenous cyclosporine in liver transplantation in Canada. Hemming, A.W., Cattral, M.S., Greig, P.D., Meisner, J., Turcotte, L., Lilly, L.B., Levy, G.A. Clinical transplantation. (1998) [Pubmed]
  22. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Chancellor, J.V., Hunsche, E., de Cruz, E., Sarasin, F.P. PharmacoEconomics. (2001) [Pubmed]
  23. Modern parathyroid surgery: a cost-benefit analysis of localizing strategies. Fahy, B.N., Bold, R.J., Beckett, L., Schneider, P.D. Archives of surgery (Chicago, Ill. : 1960) (2002) [Pubmed]
  24. Modeling the lifetime costs of rheumatoid arthritis. Gabriel, S.E., Crowson, C.S., Luthra, H.S., Wagner, J.L., O'Fallon, W.M. J. Rheumatol. (1999) [Pubmed]
  25. Institution-specific patterns of infection and Gram's stain as guides for empiric treatment of patients hospitalized with typical community-acquired pneumonia. Belliveau, P., Hickingbotham, N., Maderazo, E.G., Mazens-Sullivan, M., Robinson, A. Pharmacotherapy (1993) [Pubmed]
  26. The use of norfloxacin in a university hospital. Alaniz, C., Stumpf, J.L., Townsend, K.A. Hospital pharmacy. (1991) [Pubmed]
  27. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. Nicholson, T., McGuire, A., Milne, R. BMC cardiovascular disorders [electronic resource]. (2001) [Pubmed]
  28. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. Ann. Intern. Med. (1997) [Pubmed]
  29. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. Hillner, B.E., Weeks, J.C., Desch, C.E., Smith, T.J. J. Clin. Oncol. (2000) [Pubmed]
  30. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. Hershman, D., Sundararajan, V., Jacobson, J.S., Heitjan, D.F., Neugut, A.I., Grann, V.R. J. Clin. Oncol. (2002) [Pubmed]
  31. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. Cooper, M.R., McIntyre, O.R., Propert, K.J., Kochwa, S., Anderson, K., Coleman, M., Kyle, R.A., Prager, D., Rafla, S., Zimmer, B. J. Clin. Oncol. (1986) [Pubmed]
  32. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Gabriel, S.E., Campion, M.E., O'Fallon, W.M. Arthritis Rheum. (1994) [Pubmed]
  33. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Fagan, S.C., Morgenstern, L.B., Petitta, A., Ward, R.E., Tilley, B.C., Marler, J.R., Levine, S.R., Broderick, J.P., Kwiatkowski, T.G., Frankel, M., Brott, T.G., Walker, M.D. Neurology (1998) [Pubmed]
  34. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. van der Palen, J., Monninkhof, E., van der Valk, P., Sullivan, S.D., Veenstra, D.L. Thorax (2006) [Pubmed]
  35. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Adams, P.C., Valberg, L.S. Am. J. Gastroenterol. (1999) [Pubmed]
  36. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. Choi, H.K., Seeger, J.D., Kuntz, K.M. J. Rheumatol. (2002) [Pubmed]
  37. Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. Knijff-Dutmer, E.A., Postma, M.J., van der Palen, J., Brouwers, J.R., van de Laar, M.A. Clinical therapeutics. (2004) [Pubmed]
  38. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. Nichols, C.R., Fox, E.P., Roth, B.J., Williams, S.D., Loehrer, P.J., Einhorn, L.H. J. Clin. Oncol. (1994) [Pubmed]
  39. Rapid intraoperative immunoassay of parathyroid hormone and other hormones: a new paradigm for point-of-care testing. Sokoll, L.J., Wians, F.H., Remaley, A.T. Clin. Chem. (2004) [Pubmed]
  40. Outcome after combined carotid endarterectomy and coronary artery bypass is related to patient selection. Estes, J.M., Khabbaz, K.R., Barnatan, M., Carpino, P., Mackey, W.C. J. Vasc. Surg. (2001) [Pubmed]
  41. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. Wenzel, R., Del Favero, A., Kibbler, C., Rogers, T., Rotstein, C., Mauskopf, J., Morris, S., Schlamm, H., Troke, P., Marciniak, A. J. Antimicrob. Chemother. (2005) [Pubmed]
  42. Single-dose cefotaxime versus 3 to 5 dose cefoxitin for prophylaxis of vaginal or abdominal hysterectomy. Roy, S., Wilkins, J. J. Antimicrob. Chemother. (1984) [Pubmed]
WikiGenes - Universities